Urothelial Malignancy After Normal Hematuria Clinic Investigations: Does Non-visible Hematuria Need Reinvestigation?

Overview

Journal Urol Res Pract

Specialty Urology

Date 2024 Aug 11

PMID 39128127

Authors

Alice Thompson

Bev James

Rotimi David

Mohamed Youseff

Nicholas Gill

Matthew Jefferies

Pradeep Bose

Gokul Kanda Swamy

Affiliations

Soon will be listed here.

Abstract

Objective: Hematuria is the most common referral to Urology. Most initial evaluations are normal; however there are few medium- to long-term studies about these patients after they are discharged.

Methods: This study was a retrospective observational case-control study. Patients with normal initial investigations in our hematuria clinic (HC) over a 2-year period in 2012-2013 were included. We reviewed the electronic records of patients choosing January 1, 2021, as our reference date providing a median follow-up of 99 months. The primary aim of this study was to assess the missed urothelial malignancy (UM) rate in this cohort and also the UM rate in those re-referred to the HC.

Results: The study included 573 patients of whom 24.6% (141/573) were re-referred to urology during the study period. The overall missed UM cancer rate was 0.5% and 0.2% died as a result in this follow-up period. The UM cancer rate in those re-referred was 4.3% and of those re-referred with visible hematuria (VH) the UM cancer rate was 5.7%. No patients re-referred with non-visible VH (NVH) were diagnosed with UM. The only urological death during this time was due to UM.

Conclusion: All urological malignancy and mortality remain very low even at mediumto long-term follow-up after an initial normal HC investigation. In this study, no patients with recurrent NVH developed UM; therefore, recurrent NVH is unlikely to need reinvestigation. The risk of UM in those re-referred with VH is low but more substantial and warrants reinvestigation, which should include computed tomography urogram imaging.

References

Howard R, Golin A . Long-term followup of asymptomatic microhematuria. J Urol. 1991; 145(2):335-6. DOI: 10.1016/s0022-5347(17)38331-3. View

Barocas D, Boorjian S, Alvarez R, Downs T, Gross C, Hamilton B . Microhematuria: AUA/SUFU Guideline. J Urol. 2020; 204(4):778-786. DOI: 10.1097/JU.0000000000001297. View

Mishriki S, Nabi G, Cohen N . Diagnosis of urologic malignancies in patients with asymptomatic dipstick hematuria: prospective study with 13 years' follow-up. Urology. 2008; 71(1):13-6. DOI: 10.1016/j.urology.2007.08.031. View

Mathew A, Desai K . An audit of urology two-week wait referrals in a large teaching hospital in England. Ann R Coll Surg Engl. 2009; 91(4):310-2. PMC: 2749401. DOI: 10.1308/003588409X391767. View

Edwards T, Dickinson A, Gosling J, McInerney P, Natale S, McGrath J . Patient-specific risk of undetected malignant disease after investigation for haematuria, based on a 4-year follow-up. BJU Int. 2010; 107(2):247-52. DOI: 10.1111/j.1464-410X.2010.09521.x. View

Loo R, Whittaker J, Rabrenivich V . National practice recommendations for hematuria: how to evaluate in the absence of strong evidence?. Perm J. 2011; 13(1):37-46. PMC: 3034463. DOI: 10.7812/TPP/08-083. View

Pichler R, Heidegger I, Leonhartsberger N, Stohr B, Aigner F, Bektic J . The need for repeated urological evaluation in low-risk patients with microscopic hematuria after negative diagnostic work-up. Anticancer Res. 2013; 33(12):5525-30. View

Mariani A, Mariani M, Macchioni C, Stams U, Hariharan A, Moriera A . The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol. 1989; 141(2):350-5. DOI: 10.1016/s0022-5347(17)40763-4. View

Hawary A, Warburton H, Brough R, Collins G, Brown S, OReilly P . The '2-week wait' rule for referrals for suspected urological cancers--urgent need for refinement of criteria. Ann R Coll Surg Engl. 2008; 90(6):517-22. PMC: 2647249. DOI: 10.1308/003588408X301082. View

10.

Sells H, Cox R . Undiagnosed macroscopic haematuria revisited: a follow-up of 146 patients. BJU Int. 2001; 88(1):6-8. DOI: 10.1046/j.1464-410x.2001.02269.x. View

11.

Madeb R, Golijanin D, Knopf J, Davis M, Feng C, Fender A . Long-term outcome of patients with a negative work-up for asymptomatic microhematuria. Urology. 2009; 75(1):20-5. DOI: 10.1016/j.urology.2009.06.107. View

12.

Khadhouri S, Gallagher K, MacKenzie K, Shah T, Gao C, Moore S . The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study. BJU Int. 2021; 128(4):440-450. DOI: 10.1111/bju.15483. View

13.

Edwards T, Dickinson A, Natale S, Gosling J, McGrath J . A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic. BJU Int. 2006; 97(2):301-5. DOI: 10.1111/j.1464-410X.2006.05976.x. View

14.

Chow K, Kwan B, Li P, Szeto C . Asymptomatic isolated microscopic haematuria: long-term follow-up. QJM. 2004; 97(11):739-45. DOI: 10.1093/qjmed/hch125. View

15.

Nielsen M, Qaseem A . Hematuria as a Marker of Occult Urinary Tract Cancer: Advice for High-Value Care From the American College of Physicians. Ann Intern Med. 2016; 164(7):488-97. DOI: 10.7326/M15-1496. View